A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 14,400 shares of CLDX stock, worth $532,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,400
Holding current value
$532,944
% of portfolio
0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$35.22 - $51.88 $507,168 - $747,072
14,400 New
14,400 $604,000
Q1 2023

May 15, 2023

SELL
$34.78 - $47.43 $1.06 Million - $1.44 Million
-30,400 Reduced 45.65%
36,200 $1.3 Million
Q4 2022

Feb 14, 2023

SELL
$27.78 - $45.38 $1.49 Million - $2.43 Million
-53,500 Reduced 44.55%
66,600 $2.97 Million
Q3 2022

Nov 14, 2022

SELL
$22.7 - $37.57 $2.49 Million - $4.13 Million
-109,800 Reduced 47.76%
120,100 $3.38 Million
Q3 2022

Nov 14, 2022

SELL
$22.7 - $37.57 $2.49 Million - $4.13 Million
-109,800 Reduced 47.76%
120,100 $3.38 Million
Q2 2022

Aug 15, 2022

BUY
$20.5 - $37.33 $1.56 Million - $2.83 Million
75,900 Added 49.29%
229,900 $6.2 Million
Q1 2022

May 16, 2022

BUY
$27.64 - $39.32 $2.59 Million - $3.68 Million
93,700 Added 155.39%
154,000 $5.25 Million
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $2.15 Million - $3.39 Million
60,300 New
60,300 $2.33 Million
Q3 2021

Nov 15, 2021

SELL
$28.95 - $55.99 $2.54 Million - $4.91 Million
-87,736 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$20.71 - $35.37 $2.54 Million - $4.33 Million
-122,520 Reduced 58.27%
87,736 $2.93 Million
Q1 2021

May 17, 2021

SELL
$16.19 - $29.91 $3.1 Million - $5.72 Million
-191,300 Reduced 47.64%
210,256 $4.33 Million
Q4 2020

Feb 16, 2021

SELL
$14.99 - $22.75 $626,582 - $950,950
-41,800 Reduced 9.43%
401,556 $7.04 Million
Q3 2020

Nov 16, 2020

BUY
$9.65 - $15.19 $3.74 Million - $5.88 Million
387,300 Added 690.92%
443,356 $6.58 Million
Q2 2020

Aug 14, 2020

BUY
$1.61 - $13.41 $90,250 - $751,710
56,056 New
56,056 $729,000
Q1 2020

May 15, 2020

SELL
$1.55 - $3.07 $25,570 - $50,645
-16,497 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$2.11 - $2.8 $8,229 - $10,920
-3,900 Reduced 19.12%
16,497 $37,000
Q3 2019

Nov 14, 2019

SELL
$2.05 - $2.75 $13,529 - $18,150
-6,600 Reduced 24.45%
20,397 $43,000
Q2 2019

Aug 14, 2019

SELL
$2.43 - $5.09 $7,047 - $14,761
-2,900 Reduced 9.7%
26,997 $72,000
Q1 2019

May 15, 2019

BUY
$3.45 - $10.35 $103,144 - $309,433
29,897 New
29,897 $147,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.73B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.